FDA Pharmaceutical Regulations

American consumers benefit from having access to the safest and most advanced pharmaceutical system in the world. The main consumer watchdog in this system is FDA’s Center for Drug Evaluation and Research (CDER).Drug companies seeking to sell a drug in the United States must first test it. The company then sends CDER the evidence from these tests to prove the drug is safe and effective for its intended use. 

Best Practices
Document Title Issued by Description Available Languages Download
Best Practices in Developing Proprietary Names for Human Prescription Drug Products FDA The FDA guidance was issued to help sponsors of human prescription drug products develop proprietary names  for those products. This guidance describes best practices to help minimize  proprietary name-related medication errors and otherwise avoid adoption of proprietary names  that contribute to violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its  implementing regulations. English Complimentary
Data Integrity and Compliance With Drug CGMP Questions and Answers FDA The purpose of this guidance is to clarify the role of data integrity in current good manufacturing practice (CGMP) for drugs, as required in 21 CFR parts 210, 211, and 212. Unless otherwise noted, the term CGMP in this guidance refers to CGMPs for drugs (including biologics).This guidance provides the Agency’s current thinking on the creation and handling of data in accordance with CGMP requirements. English Complimentary
Document Title Issued by Description Available Languages Download
Referencing Approved Drug Products in ANDA Submissions FDA This guidance is intended to provide information to potential applicants on how to identify a reference listed drug (RLD), a reference standard, and the basis of submission in an abbreviated new drug application (ANDA) submission. English Complimentary
Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA FDA This guidance describes an enhanced pathway for discussions between FDA and a prospective applicant preparing to submit to FDA or an applicant that has submitted to FDA an abbreviated new drug application (ANDA) for a complex product, as defined in this guidance. Specifically, this guidance provides information on requesting and conducting product development meetings, pre-submission meetings, and mid-review-cycle meetings with FDA. English Complimentary
ANDA Submissions —Content and Format (2018) FDA This 2018 guidance is intended to assist applicants in preparing abbreviated new drug applications (ANDAs) for submission to FDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)). English Complimentary
Document Title Issued by Description Available Languages Download
Investigational New Drug Applications (INDs) —Determining Whether Human Research Studies Can Be Conducted Without an IND FDA .This guidance is intended to assist clinical investigators, sponsors, sponsor-investigators, and institutional review boards (IRBs) in determining whether research studies involving human subjects must be conducted under an investigational new drug application (IND), as described in title 21 of the Code of Federal Regulations, part 312 (21 CFR part 312) (the IND regulations). English Complimentary
Bioavailability Studies Submitted in NDAs or INDs — General Considerations (2019) FDA This  (2019) draft guidance provides recommendations to sponsors planning to include bioavailability (BA) information for drug products in investigational new drug applications (INDs), new drug applications (NDAs), and NDA supplements. English Complimentary
GRP whitepaper- Overview of FDA 5050 (b) (2) Regulatory Pathway

GRP White Paper: FDA 5050(B)(2) Regulatory Pathway (NDA)

Established under the Hatch-Waxman Amendments of 1984 to the Federal Food, Drug, and Cosmetic Act, the 505(b)(2) pathway expressly permits the US Food and Drug Administration (FDA) to rely, for approval of New Drug Applications (NDAs), on data not developed by the applicant.